By Fineline Cube 
China-based Acotec Scientific Holdings Ltd (HKG: 6669) announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its E-Peridge peripheral scoring balloon catheter. This approval marks a significant milestone for Acotec in expanding its presence in the medical device market.
E-Peridge: Indications and Mechanism
The E-Peridge peripheral scoring balloon catheter is indicated for pre-dilatation of peripheral arterial stenoses, including lesions in the iliac artery, iliofemoral artery, femoral artery, popliteal artery, and renal artery. The specialized scoring elements of the E-Peridge create focal stress points for more predictable plaque modification. This design minimizes flow-limiting dissections (Type C/D) and lowers the risk of vascular injury compared to conventional balloons, offering a safer and more effective treatment option for patients with peripheral arterial disease.
Market and Clinical Impact
The approval of the E-Peridge catheter underscores Acotec Scientific’s commitment to innovation in medical devices. By providing a more precise and safer alternative for peripheral artery dilatation, the E-Peridge aims to improve clinical outcomes and reduce complications associated with traditional balloon angioplasty. This advancement is expected to benefit patients with peripheral arterial stenosis by offering a more reliable and less invasive treatment option.-Fineline Info & Tech